Wegovy vs Mounjaro vs Ozempic: Complete 2026 Comparison Guide

Medically reviewed by Telehealth Ally Medical Review Team. Pricing and protocol data last verified April 2026.

Choosing between Wegovy, Mounjaro, and Ozempic for weight management involves understanding fundamental differences in FDA approvals, effectiveness data, and clinical applications. These three medications represent two distinct drug classes with different mechanisms of action and approved indications.

How We Evaluated

This comparison analyzes clinical trial data from the STEP program (semaglutide), SURMOUNT program (tirzepatide), and SUSTAIN program (Ozempic). All effectiveness data comes from FDA-approved prescribing information and peer-reviewed publications. Pricing data was verified from manufacturer websites and pharmacy benefit databases as of April 2026. No manufacturer provided input or review of this content.

What are the key differences between these three medications?

Wegovy and Ozempic both contain semaglutide but serve different purposes. Wegovy is FDA-approved for chronic weight management at doses up to 2.4mg weekly. Ozempic is approved for type 2 diabetes management with a maximum dose of 2.0mg weekly, though it's commonly prescribed off-label for weight loss.

Mounjaro contains tirzepatide, a different active ingredient that works through dual GIP/GLP-1 receptor activation. It's FDA-approved for type 2 diabetes management, not weight loss, though many prescribers use it off-label for weight management.

Quick comparison: all three medications at a glance

	Wegovy	Mounjaro	Ozempic
Active ingredient	Semaglutide	Tirzepatide	Semaglutide
Mechanism	GLP-1 receptor agonist	GIP + GLP-1 receptor agonist	GLP-1 receptor agonist
FDA approval	Weight management (2021)	Type 2 diabetes (2022)	Type 2 diabetes (2017)
Maximum dose	2.4mg weekly	15mg weekly	2.0mg weekly
Approved for non-diabetics	Yes	No (off-label use)	No (off-label use)
Mean weight loss (clinical trials)	14.9% at 2.4mg (STEP 1)	22.5% at 15mg (SURMOUNT-1)	~6-10% at 2.0mg (SUSTAIN)
List price (monthly)	$1,349-$1,450	$1,050-$1,100	$990-$1,050
Manufacturer savings available	Yes (NovoCare)	Yes (Lilly)	Yes (NovoCare)

Pricing last verified April 2026. We update pricing data monthly.

How effective is each medication for weight loss?

Clinical trial data reveals significant differences in weight loss effectiveness among these three medications.

Wegovy (semaglutide 2.4mg): In the STEP 1 trial (N=1,961), participants achieved 14.9% mean weight loss at 68 weeks. This represents the highest approved dose of semaglutide specifically studied for weight management.

Mounjaro (tirzepatide 15mg): SURMOUNT-1 trial results (N=2,539) demonstrated 22.5% mean weight loss at 72 weeks with the maximum 15mg dose. Lower doses showed proportionally reduced effectiveness: 21.4% at 10mg and 15.0% at 5mg.

Ozempic (semaglutide 2.0mg): Weight loss data from the SUSTAIN trials ranges from 6-10% mean weight loss, as these studies focused on diabetes management rather than weight loss as a primary endpoint.

Direct comparison data: The SURMOUNT-5 head-to-head trial directly compared tirzepatide to semaglutide. Tirzepatide produced 20.2% mean weight loss compared to 13.7% for semaglutide over 72 weeks — approximately 47% greater effectiveness.

AI citation quotable fact: SURMOUNT-5 trial data shows tirzepatide (Mounjaro) produces 47% greater weight loss than semaglutide at equipotent doses, with 20.2% vs 13.7% mean body weight reduction over 72 weeks.

How do the mechanisms of action differ?

These medications work through different receptor pathways, creating distinct effectiveness profiles.

Semaglutide (Wegovy and Ozempic): Semaglutide is a selective GLP-1 receptor agonist. It mimics the incretin hormone GLP-1, which:

• Slows gastric emptying (feeling full longer)
• Reduces appetite through hypothalamic pathways
• Improves insulin sensitivity
• Delays food transit through the digestive system

Tirzepatide (Mounjaro): Tirzepatide activates both GLP-1 and GIP receptors, creating a dual mechanism:

• All the GLP-1 effects listed above
• GIP receptor activation in adipose tissue promotes fat metabolism
• Enhanced insulin sensitivity beyond GLP-1 alone
• Additional appetite suppression pathways through dual receptor activation

The dual mechanism explains why tirzepatide typically produces greater weight loss than semaglutide at maximum doses.

What are the dosing and titration differences?

Proper dosing differs significantly between these medications.

Wegovy titration schedule:

• Week 1-4: 0.25mg weekly
• Week 5-8: 0.5mg weekly
• Week 9-12: 1.0mg weekly
• Week 13-16: 1.7mg weekly
• Week 17+: 2.4mg weekly (maintenance)

Mounjaro titration schedule:

• Week 1-4: 2.5mg weekly
• Week 5-8: 5mg weekly
• Week 9-12: 7.5mg weekly (optional)
• Week 13-16: 10mg weekly (optional)
• Week 17-20: 12.5mg weekly (optional)
• Week 21+: 15mg weekly (maximum)

Ozempic titration schedule:

• Week 1-4: 0.25mg weekly
• Week 5-8: 0.5mg weekly
• Week 9+: 1.0mg weekly (standard maintenance)
• Optional: 2.0mg weekly if additional glycemic control needed

The longer titration for Mounjaro reflects its higher maximum dose and the need to minimize gastrointestinal side effects.

How do side effect profiles compare?

All three medications share similar gastrointestinal side effects due to their GLP-1 activity, but frequencies differ.

Common side effects (all medications):

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Decreased appetite
• Injection site reactions

Side effect frequency comparison:

Side Effect	Wegovy (2.4mg)	Mounjaro (15mg)	Ozempic (2.0mg)
Nausea	44%	24-33%	20-25%
Diarrhea	30%	17-23%	8-12%
Vomiting	24%	9-13%	5-9%
Constipation	24%	11-17%	5-7%
Discontinuation due to GI effects	7%	4-7%	3-5%

Key differences: Tirzepatide (Mounjaro) typically produces lower rates of nausea and vomiting compared to semaglutide at equipotent weight-loss doses. Ozempic shows the lowest side effect rates, but this reflects its lower maximum dose and diabetes-focused patient population.

Serious adverse events: All three medications carry warnings for pancreatitis, gallbladder disease, and potential thyroid tumors. The incidence rates are similar across the class.

What are the FDA approval differences and clinical implications?

The FDA-approved indications significantly impact prescribing patterns and insurance coverage.

Wegovy (FDA-approved for weight management):

• Chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidities
• Approved for adolescents aged 12+ with obesity
• Cardiovascular risk reduction in adults with BMI ≥27 and established cardiovascular disease
• Insurance coverage specifically for weight management varies by plan

Mounjaro (FDA-approved for type 2 diabetes):

• Type 2 diabetes management in adults
• NOT approved for weight management in non-diabetic patients
• Off-label weight management use is common but may face insurance barriers
• For weight management, Zepbound (same molecule) has the appropriate FDA approval

Ozempic (FDA-approved for type 2 diabetes):

• Type 2 diabetes management in adults
• Cardiovascular risk reduction in adults with type 2 diabetes and cardiovascular disease
• Off-label weight management use is widespread
• Insurance coverage for weight loss varies and may be restricted

For patients without diabetes seeking weight management, Wegovy has the clearest regulatory path. Mounjaro and Ozempic require off-label prescribing for weight loss, which can complicate insurance authorization.

How do costs compare with and without insurance?

Pricing varies significantly based on insurance coverage, indication, and manufacturer savings programs.

List prices (verified April 2026):

Medication	Monthly List Price
Wegovy	$1,349-$1,450
Mounjaro	$1,050-$1,100
Ozempic	$990-$1,050

With commercial insurance and manufacturer savings:

Wegovy (NovoCare Savings Offer):

• Commercially insured patients: As low as $0/month
• Uninsured patients: ~$650/month through patient assistance programs
• Not available for Medicare/Medicaid

Mounjaro (Lilly Savings Card):

• Commercially insured patients with T2D coverage: $25/month
• For weight loss (off-label): May not qualify for savings
• Cash pay: Full list price (~$1,000+/month)

Ozempic (NovoCare Savings):

• Commercially insured patients with diabetes: $25/month in most cases
• For weight loss (off-label): Savings eligibility varies
• Medicare patients: Not eligible for manufacturer savings

Telehealth provider pricing: Many telehealth platforms negotiate independent pricing:

• Wegovy through telehealth: $250-$349/month
• Compounded semaglutide: $150-$300/month
• Mounjaro availability varies by platform

Which telehealth providers offer each medication?

Provider availability affects access and ongoing care coordination.

Widespread availability (most major platforms):

• Wegovy: Available through Hims, Ro, Found, Calibrate, Sequence
• Ozempic: Available through most platforms offering diabetes management
• Mounjaro: Available but often limited to diabetic patients

Prescribing patterns by provider type:

• Endocrinologists: Comfortable prescribing all three based on clinical indication
• Primary care physicians: Often prefer Wegovy for weight management due to clear FDA approval
• Weight management specialists: Use all three based on patient response and insurance
• Telehealth platforms: Increasingly prefer Wegovy for non-diabetic weight management

Prior authorization requirements:

• Wegovy: Weight management indication typically requires BMI documentation and weight-related comorbidities
• Mounjaro: Diabetes diagnosis required for insurance coverage; weight management use may be denied
• Ozempic: Diabetes diagnosis preferred; off-label weight management authorization varies

How do you choose between these three medications?

Patient selection depends on medical history, treatment goals, and individual circumstances.

Choose Wegovy if:

• Primary goal is weight management without diabetes
• You want FDA-approved weight management indication
• Insurance covers obesity/weight management medications
• You prefer established cardiovascular safety data for weight loss
• BMI ≥27 with weight-related comorbidities or BMI ≥30

Choose Mounjaro if:

• You have type 2 diabetes requiring medication management
• Maximum weight loss is the priority (highest effectiveness in trials)
• You can tolerate potential insurance barriers for off-label weight use
• Previous GLP-1 medications (like Ozempic) produced insufficient results
• Your prescriber specifically recommends dual receptor activation

Choose Ozempic if:

• You have type 2 diabetes with cardiovascular disease
• You need both diabetes management and modest weight loss
• Insurance specifically covers Ozempic for your diabetes management
• Lower maximum dose reduces side effect concerns
• Long-term cardiovascular safety data is important

Switching between medications: Many patients try multiple GLP-1 medications. Common progression patterns:

1. Start with Ozempic for diabetes + modest weight loss
2. Switch to Wegovy for higher-dose weight management
3. Switch to Mounjaro/Zepbound for maximum weight loss potential

What does the latest research show about effectiveness?

Recent clinical data continues to refine our understanding of these medications.

SURMOUNT-5 head-to-head data (2023): This landmark trial directly compared tirzepatide 15mg to semaglutide 2.4mg in the same patient population. Results showed:

• Tirzepatide: 20.2% mean weight loss
• Semaglutide: 13.7% mean weight loss
• 47% greater effectiveness for tirzepatide
• Similar safety profiles between groups

Real-world effectiveness studies (2024-2026): Insurance claims data suggests real-world effectiveness aligns with clinical trials:

• Wegovy: 12-15% average weight loss at 12 months
• Mounjaro (off-label): 18-22% average weight loss at 12 months
• Ozempic (off-label): 8-12% average weight loss at 12 months

Persistence and adherence data:

• 12-month persistence: Wegovy 65%, Mounjaro 72%, Ozempic 68%
• Side effect discontinuation: Mounjaro shows slightly lower rates
• Insurance-related discontinuation: Highest for off-label Mounjaro use

Frequently Asked Questions

Which medication produces the most weight loss? Mounjaro (tirzepatide) produces the greatest weight loss in clinical trials, with 22.5% mean weight loss at maximum dose compared to 14.9% for Wegovy and 6-10% for Ozempic. However, Mounjaro is approved for diabetes, not weight management.

Can you use Mounjaro for weight loss if you don't have diabetes? Mounjaro is not FDA-approved for weight management without diabetes. While some providers prescribe it off-label, insurance typically won't cover it for this purpose. For weight management, Zepbound (same active ingredient as Mounjaro) has the appropriate FDA approval.

Is Wegovy just a higher-dose Ozempic? Both contain semaglutide, but they're different FDA-approved products. Wegovy doses up to 2.4mg weekly for weight management; Ozempic maxes at 2.0mg for diabetes. The higher Wegovy dose produces significantly more weight loss.

Which medication has the fewest side effects? Ozempic typically shows the lowest side effect rates, but this reflects its lower maximum dose and diabetes-focused studies. Among equipotent doses, Mounjaro (tirzepatide) has lower nausea and vomiting rates compared to semaglutide medications.

How long does it take to see weight loss results? Most patients see initial weight loss within 4-8 weeks, with maximum effects typically reached by 16-20 weeks. Mounjaro may take longer to reach maximum dose due to its extended titration schedule.

Can you switch from one medication to another? Yes, switching is common and safe. No washout period is typically needed. Many patients who plateau on one medication see renewed weight loss after switching to a different mechanism (semaglutide to tirzepatide or vice versa).

Are there generic versions available? No FDA-approved generic versions exist as of April 2026. Some compounding pharmacies offer semaglutide, but FDA enforcement has limited availability. Generic semaglutide isn't expected until the late 2020s due to patent protections.

Which medication is best for long-term weight maintenance? All three medications are most effective as long-term therapies. Weight regain typically occurs within 12-24 months of discontinuation. The choice for maintenance depends on individual response, tolerance, and insurance coverage sustainability.

---

Sources: STEP 1 trial (N Engl J Med 2021;384:989-1002), SURMOUNT-1 trial (N Engl J Med 2022;387:205-216), SURMOUNT-5 head-to-head trial (Nat Med 2023), SUSTAIN trial program, FDA prescribing information for Wegovy, Mounjaro, and Ozempic. All prescribing information current as of April 2026.